Notizie su Sichuan Kelun-Biotech Biopharmaceutical

Ultime notizie

Titoli nella lingua originale della fonte.

• 
  Multiple Sacituzumab Tirumotecan (sac-TMT) Studies Selected as LBAs at ESMO 2026, OptiTROP-Lung04 and OptiTROP-Lung06 to be Presented in the Lung Cancer Session (si apre in una nuova scheda)

  22 set 2026

• 
  Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO (si apre in una nuova scheda)

  14 set 2026

• 
  Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study (si apre in una nuova scheda)

  8 set 2026

• Why Merck Stock Got Downgraded After a Massive Cancer-Vaccine Win (si apre in una nuova scheda)

  20 ago 2026

• Kelun-Biotech Announces 2026 Interim Results (si apre in una nuova scheda)

  17 ago 2026

• Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Following New TNBC Filing Has Valuation Back In Focus (si apre in una nuova scheda)

  2 ago 2026

• Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Stock May Trade At A Premium Despite Priority Review News (si apre in una nuova scheda)

  2 ago 2026

• NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC (si apre in una nuova scheda)

  30 lug 2026

• Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565 (si apre in una nuova scheda)

  27 lug 2026

• Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy (si apre in una nuova scheda)

  16 lug 2026

• Can Dow Jones' Merck Nab $25 Billion With Its Smart Bomb For Cancer? (si apre in una nuova scheda)

  15 lug 2026

• Merck ADC, in China study, shows potential to replace chemo in lung cancer (si apre in una nuova scheda)

  15 lug 2026

• Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma (si apre in una nuova scheda)

  15 lug 2026

• Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma (si apre in una nuova scheda)

  15 lug 2026